Title: Cross-sectional and Longitudinal Associations Between Circadian Alignment and Cardiovascular-Kidney-Metabolic Syndrome in US Adults

Running title: Associations of Circadian Alignment and CKM risk and outcomes

Author information

Bolin Li [1,†], Xinping Kang [2,†], Yushan Liu [3], Qing Zhang [1], Lele Cheng [4], Kai Lan[1], Yongxin Yang [1], Jialing He [1], Zhen Zhang [1], Miaomiao Cao[4], Rong Jie [6*]*

[1] Department of Cardiology, The Third People's Hospital of Chengdu, Affiliated Hospital of SouthwestJiaotong University, Chengdu, 610014, Sichuan, China

[2] Dermatology, Xi'an Jiaotong University First Affiliated Hospital, Xi'an, Shaanxi 710004, China

[3] Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China

[4] Department of Medical Imaging, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, , Shaanxi 710004, China

[5] The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China

[†]Denotes joint first author

[*]Denotes joint corresponding author

Correspondence

Rong Jie, The Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China. E-mail: 13186255110@163.com

Miaomiao Cao, Department of Medical Imaging, the First Affiliated Hospital of Xi'an Jiaotong

University, Xi'an, Shaanxi 710004, China. E-mail: xjtucm@163.com

Zhen Zhang, Department of Cardiology, The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu, 610014, Sichuan, China. E-mail: zhangzhen@swjtu.edu.cn

Abstract

BACKGROUND AND AIMS: Cardiovascular-kidney-metabolic (CKM) syndrome is a novel consensus defined by its multi-systemic and progressive nature. Circadian rhythm is a critical modulator of metabolic health. However, no previous studies assessed the associations between circadian alignment and CKM risk and outcomes.

METHOD: This analysis utilized 2011-2014 NHANES data to examine adults (≥20 years) with cardiovascular-kidney-metabolic risk profiles. The circadian alignment evaluates the circadian light-activity synchronization through phasor analysis, which includes the assessment of phasor magnitude and acrophase. These parameters are subsequently categorized into quintiles for further study. Cross-sectional and longitudinal models were implemented to evaluate associations with CKM risk and adverse outcomes.

RESULTS: 7,493 participants, representing 152,571,804 US adults (median 6.83-year follow-up). Participants with the shortest magnitude, characterized by the least overlap

between light and activity cycles, not only have the highest risk of CKM (odds ratio [OR] 1.61, 95% CI 1.19–2.16) but also showed high all-cause mortality ([aHR] 1.84, 95% CI 1.37–2.47) and cardiovascular mortality (SHR 2.10, 95%CI 1.31–3.36). We observed a potential linear negative correlation between continuous phasor magnitude and the risk of CKM, as well as adverse outcomes (P-overall <**0.001**). Similar correlations were found in CVD, CKD, and DM separately. Males and older adults had elevated CKM incidence and all-cause/cardiovascular mortality versus female/younger counterparts. However, there was no statistical significance between phasor acorphase and CKM risk and adverse outcomes.

CONCLUSION: Individuals with lower phasor magnitude， characterized by the least overlap between light and activity cycles，tend to have higher risks for CKM syndrome and adverse outcomes. These findings underscore quantifying circadian as a modifiable target for CKM primary prevention.


Circadian Alignment--excellent
Activity
light(10^3)
Time(hour)
Activity inensity
Cox proportional hazards regression(All-cause mortality)
Circadian Alignment
very bad
bad
good
very good
excellent
Cumulative Hazard
Time(month)
Circadian Alignment--very bad
Activity
light(10^3)
Time(hour)
Activity inensity
Competing-risks regression(Cardiovascular mortality)
Circadian Alignment
very bad
bad
good
very good
excellent
Cumulative Incidence
Time(month)

Introduction

Cardiovascular-kidney-metabolic (CKM) syndrome stresses the pathophysiological interplay between heart disease, kidney disease, and metabolic risk factors[1]. Almost 90% of American adults suffer from CKM syndrome, and 15% end up in the advanced stages (stage 3-4) in 2011-2020[2]. CKM syndrome results in a great economic burden and has emerged as the primary cause of mortality in 2021[3]. Therefore, early screening of the targeted populations at risk is crucial for effectively preventing and managing CKM syndrome.

Circadian rhythm operates on a roughly 24-hour cycle, coordinating the timing of physiological processes to keep synchrony with environmental cues, primarily the light-dark cycle. These oscillations regulate sleep architecture, hormone release[4], metabolism[5,6], eating habits[7], or digestion. Disruption of circadian rhythm, whether due to lifestyle factors, shift work, or genetic predispositions, can desynchronize the internal circadian system from the external environment, leading to a broad spectrum of health disorders[8,9].

Diabetes mellitus and metabolic syndrome patients exhibit disrupted circadian rhythms, which correlate with elevated risks of hypertension[10] and cardiovascular complications[8]. Also, researchers demonstrated the impacts of circadian rhythm disruption on renal physiology, including glomerular filtration efficiency, tubular reabsorption, abnormal sodium handling, renin-angiotensin-aldosterone system (RAAS) dynamics, and compromising systemic blood pressure regulation[9], suggesting that the renal molecular clock's alteration affects both intrarenal and systemic metabolic

processes. Population-level quantification of intricate relationship between circadian rhythm disruptions and CKM may provide strategies for modifiable prevention of CKM syndrome.

Here, we collected data from the NHANES study cohort, using phasor analysis to examine the associations of circadian alignment and CKM risk and outcomes, aiming to identify the prospective targets for CKM prevention and management.

Method

Data source and study population

Data in the present investigation was retrieved from the National Health and Nutrition Examination Survey (NHANES), which is a national, serial, one-time probability sampling design program to track health and nutrition patterns across age groups. Approval for the NHANES protocol was granted by the National Center for Health Statistics Ethics Review Board. The ethics approval was not required for this study because it was a secondary analysis based on a publicly available database and did not include identified personal information. The present research adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) for reporting observational studies in epidemiology, specifically for cross-sectional studies.

NHANES data from the two-year cycles of 2011-2012，2013-2014 are screened in this study. Of all 19,931 participants in the 2011-2014 NHANES survey, we excluded those aged＜20 years and lacking information of CKM syndrome determination, survival outcome, and light and/or activity data. Consequently, a total of 7493

participants were enrolled.

Phasor analysis

Light exposure and physical activity patterns were objectively monitored were measured by physical activity monitoring devices in NHANES survey([11]). Phasor analysis evaluates the 24-hour light intensity and motility fluctuations by two variables including phasor magnitude and acrophase[12].Light exposure has a nonlinear impact on the human circadian system [13]. Light intensity data were adjusted using a logistic curve to address the circadian system's nonlinear responses to light. Because measurement devices could not capture detailed wavelength information, we established a maximum light threshold of 10,000 lux — exceeding values being reduced to this level based on established biological thresholds.

Circadian stimulation (CS) exposure values were recorded utilizing the Daysimeter, followed by transformation via a logistic stimulus-response function, covering the spectrum from threshold to saturation[12]. Behavioral entrainment was assessed through circular cross-correlations, revealing timing-related relationships. Normalization involved dividing by total samples, adjusting by standard deviations, ensuring correlation coefficients range from -1 to 1[14]. This analysis provides a robust framework for understanding circadian stimulation's impact on behavioral responses, utilizing statistical methods to extract meaningful correlations from complex datasets. The phasor magnitude indicates the extent of alignment between an individual's light-dark cycle and his/her activity cycle, while the phasor acrophase reflects the temporal relationship between the two cycles.

Assessment of CKM conditions

In the current study, CKM conditions include chronic kidney disease (CKD) ,cardiovascular disease (CVD) , diabetes mellitus (DM) as recommended(15). CVD was defined as history of coronary heart disease, angina, heart attack, heart failure, and stroke. CKD risk is classified based on estimated GFR classification and albumin levels, with moderate risk serving as the threshold for albuminuria as suggested(1,16), with moderate risk serving as the threshold for defining CKD as a binary variable Diabetes mellitus was determined as HbA1c≥6.5%, fasting glucose>7.0mmol/L, self-reported diagnosis of diabetes, or usage of diabetes medications. CKM was defined as the presence of at least one comorbid CKM condition(15).

Outcome

This study evaluated four adverse endpoints including mortality from all causes, cardiovascular mortality, cancer mortality, and premature mortality. Total mortality was operationalized as any fatality confirmed by national death registries, irrespective of etiology. Cardiovascular mortality was restricted to deaths with an underlying cause classified under ICD-10 codes I00-I99, including ischemic heart disease (I20-I25), myocardial infarction (I21-I22), heart failure (I50), and cerebrovascular events (I60-I69). Cancer mortality comprised deaths attributable to malignant neoplasms (C00-C97). Premature death was characterized by mortality occurring prior to 70 years of age. Detailed definition according to the International Classification of Disease 10th

Revision (2019 edition).

Covariates

Potential confounders, including age as a continuous variable, gender (female or male), racial and ethnic background (Hispanic; non-Hispanic Black, non-Hispanic White, and other [multiracial and any race other than Black or White]), smoking behavior (current, former, <100 cigarettes in life or never smoker), and alcohol use (nondrinker, < 1/week, 1/week to 1/day, 1/day above), education (less than high school, high school graduate, some college, college graduate and above or others), marital status(marital, unmarried or unknown), household income(<20000, 20000-44900, 45000-74900, >75000 and unknown), and Body Mass Index(BMI)(<18.5, 18.5-25, 25-30, ≥30). All the covariates are self-reported, mutually exclusive categories. Demographic characteristics and lifestyle habits were obtained by personal interview, and BMI was derived from physical measurements at the Mobile Examination Center.

Statistic analysis

Analytical approaches incorporated CDC-recommended NHANES sampling weights (WTINT2YR) to account for complex survey design effects, including cluster sampling and non-response bias. All statistical procedures adhered to CDC analytic guidelines for complex survey data. Quintiles grouped phasor magnitude and angle to characterize the research population. Continuous measures reported as weighted means ± standard error (SE)(normal) or medians with 95% confidence intervals

(CIs)(skewed), categorical variables as adjusted proportions. Group comparisons utilized Wald-F, Kruskal Wallis, and Rao-Scott χ^2 tests. The cross-sectional analysis of the relationship between phasor magnitude (continuous variables) and CKM risk utilizes binary logistic weighted regression. Longitudinal analyses addressed cause-specific mortality rate, based on Cox proportional hazards regression models Model 1 adjusted for age and sex in logistic regression (adjusted for the number of CKM conditions in cox regression). Model 2 further controlled for other confounding variables such as race and ethnicity, education level, marital status, and household income. Model 3 further accounted for smoking, BMI, and alcohol consumption. Additionally, the Fine and Gray method was applied to estimate the competing risks between cardiovascular mortality, cancer mortality, and other types of mortality. And follow-up period had a median of 6.83 years (interquartile range [IQR] 5.75–7.92). To assess the potential linear relationship between phasor magnitude and CKM, as well as adverse outcomes, restricted cubic splines were applied, with adjustment for the covariates in Model 3.

All our statistical analyses used R4.4.1 (R Foundation for Statistical Computing, Vienna, Austria) statistical software, except for competing risk regression analysis was conducted using STATA 17.0 based on the Fine and Gray model.

Results

Baseline characteristics of participants

Descriptive data grouped by phasor magnitude quintile are presented in Table 1

below. The final enrolled participants (n=7493) were representative of 152,571,804 US adults. Approximately 48% of them were male and 68% were non-Hispanic whites, with a weighted median age of 50 years. The median phasor magnitude and acrophase were 0.36 (0.28-0.43) and 3(0-6). In the present study, the proportion of CKM, CKD, CVD, DM was 28% (n=42695684), 15%(n=22957893), 9.7% (n=14838662), 14% (n=21783886), respectively. Additionally, while the proportion of young adults aged 20-39 years, non-Hispanic blacks, and non-married status were prone to negatively related with phasor magnitude, that of older adults aged over 60 years, non-Hispanic whites, married status showed a positive correlation with phasor magnitude.

Association between circadian alignment and CKM risk

Firstly, we evaluated the relationship of phasor variables (magnitude and acrophase) and CKM risk. There was no statistically difference of CKM prevalence between different magnitude quintiles groups, despite Q1 group has the highest proportion (Table 1). Three logistic regression models were built to identified the association between phasor magnitude and CKM risk (Figure 2A). Model 1(adjusted for age and sex) shows stepwise increased trends for CKM risks with reduced phasor magnitude (P trends < 0.001). Specifically, participants in Q1 group (the shortest magnitude) are 80% (odds ratio [OR] 1.80, 95% CI 1.41-2.31) more likely to have CKM compared with the reference group (Q5 group). Although further adjusted for potential confounders slightly attenuated the association in model 2 and 3, the first quartile (Q1) group always demonstrated highest risk of CKM, with an OR of 1.61 (95%

CI: 1.19–2.16) in the fully adjusted model 3. Figure 2B-D also revealed that shorter phasor magnitude exhibited a higher risk for each separate CKM condition (CKD, CVD, DM) (P<0.001). However, the impacts of phasor magnitude on CVD (OR 1.66, 95% CI 1.16-2.37) and CKD risk (OR 1.62,95% CI 1.14-2.30) are greater than on DM (OR 1.41, 95% CI 1.06-1.87) in the fully adjusted model 3.

The restricted cubic spline (RCS) analysis revealed a linear negative correlation between continuous phasor magnitude and the risk of CKM (P-overall <0.001, P-nonlinearity = 0.48), as illustrated in Figure **1**A based on Model3(adjusted for age and sex, race, ethnicity, education level, marital status, household income, smoking, alcohol consumption, and BMI). Similar correlations were observed in CVD (P-overall <0.001, P-nonlinearity = 0.43), CKD (P-overall <0.001, P-nonlinearity = 0.43), and DM(P-overall <0.001, P-nonlinearity = 0.14) (Figures 1B-D). Furthermore, subgroup analyses were conducted to identify the correlations between continuous phasor magnitude and the risks of CKM and each separate CKM conditions, stratified by sex (female, male) and age (grouped by 20-39, 40-59, 60 and beyond). The curves showed similar linear negative correlations across different subgroups, as shown in Figure 1. Interestingly, male and older individuals with short phasor magnitude were more likely to have CKM and each separate CKM condition, compared with their female and younger counterparts.

There was no statistical significance between acrophase quintiles and the CKM risk, as well as CVD, CKD, and DM risks in the adjusted logistic regression models (sup. Fig2). However, RCS curves indicated U-shaped associations between acrophase

and CKM (P-overall <0.001, P-nonlinearity = 0.19), CVD (P-overall <0.0001, P-nonlinearity = 0.23), in which small and large acrophase were related to higher CKM and CVD risks compared with median acrophase. Moreover, acrophase was negatively correlated with CKD risk (P-overall <0.001, P-nonlinearity = 0.50), and positively correlated with DM risk (P-overall <0.001, P-nonlinearity = 0.52) (sup. Fig1). Similar to phasor magnitude, male and older individuals exhibited higher risks of CKM and each separate CKM conditions, compared with their female and younger counterparts in the subgroup analyses (sup. Fig1).

Association between circadian alignment and adverse outcomes

Secondly, we explored the relationships between phasor variables (magnitude and acrophase) and adverse outcomes (all-cause mortality, cardiovascular mortality, malignant neoplasms mortality, and premature mortality). The cumulative hazard function (CHF) were used to assess risks for adverse outcomes by magnitude quartiles groups are shown in Figure 4. During a median follow-up of 6.83 years [interquartile range (5.75, 7.92)], short phasor magnitude was associated with a poor prognosis, especially for the first magnitude quartile (Q1) group. heat map in figure 3 reveals the mortality increases with the number and overlap of diseases and decreases with the phasor magnitude overall. Additionally, the percentages of each adverse outcomes seemed to be increased with the number of CKM conditions, but irrespective of type of CKM overlaps (Fig4).

In the Cox proportional hazards models, Q1 group was independently related to

high all-cause mortality (adjusted hazard ratio [aHR] 1.45, 95% CI 1.07–1.98) and cardiovascular mortality (aHR 2.14, 95% CI 1.39–3.18), after adjusted the number of CKM conditions in model 1, and this relationship remained after adjustment for other confounders in mode 2 and model 3 (Figure 5a). Notably, Q1 group is 110% (aHR 2.10, 95%CI 1.374–3.36) more likely to die from cardiovascular disease compared to Q5 group in the fully adjusted model 3 (Figure 6B). No statistical significance was identified in the association between magnitude quartiles and malignant neoplasms mortality (aHR 1.02, 95% CI 0.62–1.67), premature mortality (aHR 1.80, 95% CI 0.94–3.34) (Figure 6C-D). RCS analyses in figure 5 further supported the linear negative correlations between continuous phasor magnitude and adverse outcomes, including all-cause mortality (P-overall <0.001, P-nonlinearity = 0.16), cardiovascular mortality (P-overall <0.001, P-nonlinearity = 0.39), malignant neoplasms mortality (P-overall <0.001, P-nonlinearity = 0.11), and premature mortality (P-overall <0.001, P-nonlinearity = 0.69). When stratifying the study population by sex, age, and number of CKM conditions, similar trends were found for all-cause mortality and cardiovascular mortality, but varied for malignant neoplasms mortality and premature mortality (Figure 5). Male, older individuals and the more CKM overlap conferred higher risk of all-cause mortality and cardiovascular mortality, compared with their female and younger counterparts as well as those with less CKM overlap. Furthermore, the largest gap of adverse outcomes between sex, age group, and number of CKM overlap was all found in those with short magnitude.

However, there was no statistical significance between phasor acorphase and

adverse outcomes (sup Fig4) mortality, despite a linear correlation was found for all-cause mortality (P-nonlinearity=0.90), cardiovascular mortality (P-nonlinearity=0.30), malignant neoplasms mortality (P-nonlinearity=0.09), and premature mortality (P-nonlinearity=0.43) (sup Fig 3).

Discussion

Based on the literature review, this is the first cross-sectional and longitudinal study to investigate whether circadian alignment related to the CKM risk and outcomes in US adults by using a nationally representative sample. Results indicated that phasor magnitude (coupling extent of activity and light) negatively related to the risks of CKM and adverse outcomes mortality (all-cause and cardiovascular mortality). Besides, Males and older adults had elevated CKM incidence and all-cause/cardiovascular mortality versus female/younger counterparts. Additionally, higher all-cause and cardiovascular mortality frequencies among participants with greater numbers of coexisting CKM conditions. The largest gaps were observed in participants with short phasor magnitude.

In essence, circadian dysfunction and CKM are both significant public health issues[17,18]. Understanding its correlation is not only important for basic biological research but also has implications for human health and well-being. Circadian rhythm is a complex and dynamic interplay between the internal cellular processes, physiology, behaviors, and the external environment[19–21]. Light-dark and activity-rest pattern are two important measures for evaluating circadian dysfunction. However, most studies

focus on them separately or only describe the temporary mismatch between light and activity, such as chronotypes (early chronotypes/early birds, late chronotypes/night owls) and social jet lag[20]. In the present study, we use phasor analysis (two continuous variables) to quantify the periodic degree of coupling between light and activity cycles, which has been proved as a better measure to describe circadian dysfunction (11,14,22). Although the relationship between circadian alignment and CKM has not been previously reported, the association for DM presented here was consistent with the previous study by Xiao et al. that shorter phasor magnitude was linked to an increased risk of diabetes, along with elevated levels of HOMA-IR, OGTT and fasting insulin (11). Growing evidence also showed that circadian dysfunction has an impact on CVD and CKD. Two large-scale population studies revealed insomnia associated with an increased risk for acute myocardial infarction[23] and incident heart failure[24]. Nighttime artificial light exposure and late-night dietary intake exhibit quantifiable associations with heightened metabolic syndrome predisposition and elevated cardiovascular morbidity risk1[25]. A mendelian randomization study including 465,814 UK Biobank participants demonstrated short sleep duration (<6 hours) was significantly related to a higher risk of CKD stages 3–5(26). Our findings support and further extend the current literature by demonstrating that shorter phasor magnitude was associated with high risk of CVD, CKD, and CKM. This would be of interest for screening individuals who are at high risk of CKM.

Existing studies have examined the connections between sleep behaviors and negative health outcomes through analysis of the UK Biobank dataset. In contrast to

individuals with restorative sleep, those experiencing inadequate sleep demonstrated elevated risks of mortality from all causes (hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.13–1.34) and cardiovascular disease-related deaths (HR 1.39, 95% CI 1.19–1.62)[27]. And this association can be exacerbated by low physical activity. Further, among individuals with diabetes, it showed similar results that a healthy sleep pattern was associated with a lower risk of all-cause mortality[28], which is consistent with our finding that the shortest magnitude (suboptimal alignment of activity and light cycles) was independently related with elevated risks of all-cause and cardiovascular-related deaths in DM population. A pooled analysis encompassing 958,674 individuals across sixteen prospective studies demonstrated that non-traditional work schedules (e.g., rotating/night shifts) may elevate the likelihood of mortality from all causes and cardiovascular-specific events relative to conventional daytime employment[29]. Furthermore, our analysis demonstrated a similar inverse association between phasor magnitude and mortality rates within the CKM cohort, a pattern consistently observed in CVD-related comorbidities and additional CKM-related health states, CKD. Wu et al. suggested that disorders including DM, coronary artery disease, and depression, partially mediate the causal relationship that short sleep duration was negatively correlated with lifespan[30]. Our findings that more concomitant CKM conditions, and shorter phasor magnitude showed higher mortality risk may strengthen the opinion that circadian alignment and disease's status have a potential synergistic effect for poor outcomes.

Interestingly, male and older individuals were more likely to have CKM as well as

present with higher risks of all-cause and cardiovascular mortality, especially for those with short magnitude. Indeed, sex and age-related disparities for circadian and CKM have been well-recognized. The ‘‘lateness’’ of chronotypes reaches a maximum around age 20, and then shift earlier with increasing age. In comparison with women, men show their ‘‘lateness’’ of chronotypes later and maintain most of their adulthood. Individuals aged over 60 years old mostly showed early chronotype[20,31] . Men and people aged over 65 have higher prevalence of advanced CKM stages[2] . Although the underlying mechanisms have not been elucidated, interaction of multiple factors, such as hormonal levels, 24-hour gene expression rhythms, and social factors et al., might involve in the different vulnerabilities to circadian dysfunction, CKM risk and outcomes between sex and age.

Regarding phasor acorphase, there was no statistical significance between acorphase and CKM risk and outcomes. Because the acrophase of light and activity peaks may be shifted forward or backward. Positive and negative acrophases may offset each other, thereby weakening their association with diseases and adverse outcomes.

Our study has some limitations. A key limitation of this observational design is the inability to establish causality between CKM-related risk factors and the coherence of the activity cycle and light cycle. Some studies also show cardiovascular disease can lead to circadian rhythm disorder, and vice versa. Second, we did not rule out all potential confounding factors that could influence the results, like seasons, genetic susceptibility, and underlying health conditions. Third, individuals with more severe diseases and hospitalized patients may have regular routines due to physician

recommendations, leading to high magnitude; however, their disease severity and mortality rates are elevated. Fourth, we didn't consider other daily activities such as physical exercise and meal timing, which are likely related to health status.

Reduced alignment between circadian rhythms and daily activity patterns independently predicts incident cardiometabolic-kidney multimorbidity (CKM) and adverse outcomes. Our findings, integrating novel phasor analysis with competing-risk models, position circadian optimization as a modifiable target for primary prevention—particularly in males and older adults, who face disproportionate CKM burdens.

Public health strategies should prioritize scalable circadian interventions (e.g., community-based light exposure guidelines, age-tailored physical activity programs) to curb the rising global burden of metabolic-kidney disorders. Mechanistic trials evaluating circadian-aligned therapies in high-risk populations are urgently needed.

Funding

This study was supported by the National Natural Science Foundation of China (No.82200500) and (No.82400407).

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No.82200500) and (No.82400407). The authors would like to thank Cheng lele, for his help in the Methodology.

Declaration

1. Competing interests

The authors declare no competing interests, including financial benefits, non-monetary associations, or institutional engagements that could directly/indirectly influence the research objectives, analytical processes, or conclusions outlined in this work.

2. Ethics approval

All data in this study are included in NHANES. National Center for Health Statistics (NCHS) Ethics Review Board (ERB) provides centralized ethical oversight of all human subject protections in NCHS research initiatives and did not require additional ethical review by the investigator's affiliated institution.

3. Consent

Written consent documentation was secured from all enrolled subjects through standardized protocols that explicitly authorized anonymized data utilization and inclusion in scholarly publications.

4. Data

All data generated or analysed during this study are included in NHANES from the 2011–2012 and 2013–2014 cycles. Which is available for publication at *https://www.cdc.gov/nchs/nhanes/index.htm*

5. Authors' contribution statements

Conceptualization: Rong Jie, Bolin Li

Data curation: Rong Jie, Miaomiao Cao

Formal analysis: Zhen Zhang, Kai Lan

Vusualisation: Yushan Liu, Yongxin Yang

funding acquisition: Lele Cheng, Qing Zhang

project administration: Zhen Zhang

software: Rong Jie, Jialing He

Methodology: Bolin Li, Xinping Kang, Lele Cheng

Writing-original draft: Xinping Kang, Bolin Li

Review &editing: Miaomiao Cao, Bolin Li

References

1. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023 Nov 14;148(20):1606–35.

2. Aggarwal R, Ostrominski JW, Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020. JAMA. 2024 Jun 4;331(21):1858–60.

3. Mortality in the United States, 2021 [Internet]. [cited 2024 Jun 15]. Available from: https://stacks.cdc.gov/view/cdc/122516

4. Alvord VM, Kantra EJ, Pendergast JS. Estrogens and the circadian system. Semin Cell Dev Biol. 2022 Jun;126:56–65.

5. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science. 2010 Dec 3;330(6009):1349–54.

6. Shi S qun, Ansari T, McGuinness OP, Wasserman DH, Johnson CH. Circadian disruption leads to insulin resistance and obesity. Curr Biol [Internet]. 2013 Mar 4 [cited 2024 Jun 15];23(5):372–81. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595381/

7. Rao F, Xue T. Circadian-independent light regulation of mammalian metabolism. Nat Metab. 2024 Jun;6(6):1000–7.

8. Manoogian ENC, Zadourian A, Lo HC, Gutierrez NR, Shoghi A, Rosander A, et al. Feasibility of time-restricted eating and impacts on cardiometabolic health in 24-h shift workers: The Healthy Heroes randomized control trial. Cell Metab. 2022 Oct 4;34(10):1442-1456.e7.

9. Mohandas R, Douma LG, Scindia Y, Gumz ML. Circadian rhythms and renal pathophysiology. J Clin Invest. 2022 Feb 1;132(3):e148277.

10. Škrlec I, Talapko J, Džijan S, Cesar V, Lazić N, Lepeduš H. The Association between Circadian Clock Gene Polymorphisms and Metabolic Syndrome: A Systematic Review and Meta-Analysis. Biology (Basel). 2021 Dec 24;11(1):20.

11. Xiao Q, Durbin J, Bauer C, Yeung CHC, Figueiro MG. Alignment Between 24-h Light-Dark and Activity-Rest Rhythms Is Associated With Diabetes and Glucose Metabolism in a Nationally Representative Sample of American Adults. Diabetes Care. 2023 Dec 1;46(12):2171–9.

12. Rea MS, Bierman A, Figueiro MG, Bullough JD. A new approach to understanding the impact of circadian disruption on human health. J Circadian Rhythms. 2008 May 29;6:7.

13. Rea MS, Figueiro MG, Bierman A, Bullough JD. Circadian light. Journal of Circadian Rhythms [Internet]. 2010 Feb 13 [cited 2024 Dec 15];8(0). Available from: https://jcircadianrhythms.com/articles/10.1186/1740-3391-8-2

14. Miller D, Bierman A, Figueiro M, Schernhammer E, Rea M. Ecological measurements of light exposure, activity, and circadian disruption. Light Res Technol [Internet]. 2010 Sep [cited 2024 Nov 24];42(3):271–84. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596178/

15. Lassen MCH, Ostrominski JW, Claggett BL, Packer M, Zile M, Desai AS, et al. Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF. European Journal of Heart Failure [Internet]. 2024 Aug 1 [cited 2024 Nov 21];26(8):1762–74. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3304

16. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024 Apr;105(4S):S117–314.

17. Di H, Guo Y, Daghlas I, Wang L, Liu G, Pan A, et al. Evaluation of Sleep Habits and Disturbances Among US Adults, 2017-2020. JAMA Netw Open. 2022 Nov 1;5(11):e2240788.

18. Zhu R, Wang R, He J, Wang L, Chen H, Niu X, et al. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages by Social Determinants of Health. JAMA Netw Open. 2024 Nov 4;7(11):e2445309.

19. Zielinska-Dabkowska KM, Schernhammer ES, Hanifin JP, Brainard GC. Reducing nighttime light exposure in the urban environment to benefit human health and society. Science. 2023 Jun 16;380(6650):1130–5.

20. Gentry NW, Ashbrook LH, Fu YH, Ptáček LJ. Human circadian variations. J Clin Invest. 2021 Aug 16;131(16):e148282.

21. Patke A, Young MW, Axelrod S. Molecular mechanisms and physiological importance of circadian rhythms. Nat Rev Mol Cell Biol. 2020 Feb;21(2):67–84.

22. Gan Y, Yang C, Tong X, Sun H, Cong Y, Yin X, et al. Shift work and diabetes mellitus: a meta-analysis of observational studies. Occup Environ Med. 2015 Jan;72(1):72–8.

23. Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation. 2011 Nov 8;124(19):2073–81.

24. Zielinska-Dabkowska KM, Schernhammer ES, Hanifin JP, Brainard GC. Reducing nighttime light exposure in the urban environment to benefit human health and society. Science. 2023 Jun 16;380(6650):1130–5.

25. Meléndez-Fernández OH, Liu JA, Nelson RJ. Circadian Rhythms Disrupted by Light at Night and Mistimed Food Intake Alter Hormonal Rhythms and Metabolism. Int J Mol Sci. 2023 Feb 8;24(4):3392.

26. Park S, Lee S, Kim Y, Lee Y, Kang MW, Kim K, et al. Short or Long Sleep Duration and CKD: A Mendelian Randomization Study. J Am Soc Nephrol. 2020 Dec;31(12):2937–47.

27. Huang BH, Duncan MJ, Cistulli PA, Nassar N, Hamer M, Stamatakis E. Sleep and physical activity in relation to all-cause, cardiovascular disease and cancer mortality risk. Br J Sports Med. 2022 Jul;56(13):718–24.

28. Li J, Yin J, Luo Y, Ma T, He L, Xie H, et al. Association of healthy sleep pattern with the risk of cardiovascular disease and all-cause mortality among people with diabetes: A prospective cohort study. Diabetes Res Clin Pract. 2022 Apr;186:109822.

29. Su F, Huang D, Wang H, Yang Z. Associations of shift work and night work with risk of all-cause, cardiovascular and cancer mortality: a meta-analysis of cohort studies. Sleep Med. 2021 Oct;86:90–8.

30. Wu Y, Zhang CY, Liu X, Wang L, Li M, Li Y, et al. Shared genetic architecture and causal relationship between sleep behaviors and lifespan. Transl Psychiatry. 2024 Feb 22;14(1):108.

31. Roenneberg T, Kuehnle T, Juda M, Kantermann T, Allebrandt K, Gordijn M, et al. Epidemiology of the human circadian clock. Sleep Med Rev. 2007 Dec;11(6):429–38.

Figure legend

Figure 1. Restricted cubic spline curves for association between phasor magnitude and CKM* risk (A-C), CVD* risk (D-F), CKD* risk (G-I) and DM* risk(J-L). All plots are performed using multivariate logistic regression based on Model 3. The hazard ratio is represented by a red line and the 95% confidence interval is represented by the shaded area.The right two plots of each row illustrate subgroup analyses adjusted for sex and age.

CKM: cardiovasculer-kidney-metabolic syndrome

CKD: chronic-kidney disease

CVD: cardiovascular disease

DM: diabetes mellitus

Figure 2. Association between phasor magnitude and CKM risk (A), CKD risk (B), CVD risk (C) and DM risk(D). All plots are performed using multivariate logistic regression based on Model 1 (age and sex), Model 2 (additional race and ethnicity, education level, marital status, and household income), Model 3(additional smoking, alcohol consumption, and BMI). ORs and 95% CI are presented comparing with Q1 (referrence group).

BMI: body mass index

Figure 3. The incidence of mortality rate by phasor magnitude. Diffrerences between

the all-cause mortality and ckm condition combination(A) or the number of ckm conditions(B). cardiovascular mortality (C - D), cancer mortality (E -F) and premature mortality (G - H). The heatmap using mortality unadjusted. the color intensity represents the level from low (blue) to high (red).

Figure 4. Cumulative hazard function curves competing risks regression analysis under Fine and Gray models estimates for selected endpoints, cardiovascular mortality(B), cancer mortality(C), cox (all-cause mortality(A), and premature mortality(D) by phasor magnitude.

Figure 5. RCS curves for association between phasor magnitude and all-cause mortality (A-D), cardiovascular mortality (E-H), cancer mortality (I-L) and premature mortality(M-P). All plots are performed using multivariate Cox proportional hazards regression based on Model 3. The hazard ratio is represented by a red line and the 95% confidence interval is represented by the shaded area.

The right 3 plots of each row illustrate subgroup analyses stratified by sex, age and the number of ckm conditions.

Figure 6. Association between phasor magnitude and all-cause mortality (A), cardiovascular mortality (B), premature mortality (C) and cancer mortality(D). A and D plots are performed using multivariate Cox proportional hazards regression while B and C plots using competing risks regression analysis under Fine and Gray models

- Model 1 (age and sex) , Model 2 (additional race and ethnicity, education level, marital status, and household income), Model 3(additional smoking, alcohol consumption, and BMI). HRs and 95% CI are presented comparing with Q1 (referrence group).

Table 1. **Baseline characteristics of participants**

	Phasor magnitude					
	Q1	Q2	Q3	Q4	Q5	p value
Phasor magnitude,median(IQR)	0.20 (0.16.0.23)	0.29 (0.27.0.31)	0.35 (0.34.0.37)	0.41 (0.39.0.42)	0.48 (0.46.0.51)	<0.001
Age (%)						<0.001
20-39	10,018,956 (37%)	10,085,641 (34%)	9,227,014 (31%)	8,712,832 (27%)	8,053,188 (24%)	
40-59	10,626,242 (39%)	11,299,531 (38%)	11,423,870 (38%)	13,428,396 (42%)	13,776,325 (40%)	
60+	6,344,918 (24%)	8,011,075 (27%)	9,353,236 (31%)	9,989,215 (31%)	12,221,364 (36%)	
sex(%)						0.004
female	12,660,172 (47%)	14,483,253 (49%)	16,883,885 (56%)	18,012,237 (56%)	17,773,751 (52%)	
male	14,329,944 (53%)	14,912,994 (51%)	13,120,235 (44%)	14,118,207 (44%)	16,277,127 (48%)	
Race and ethnicity(%)						<0.001
Hispanic	1,465,699 (5.4%)	1,746,710 (5.9%)	1,829,989 (6.1%)	2,028,394 (6.3%)	1,915,746 (5.6%)	
Non-Hispanic Black	4,784,693 (18%)	3,786,816 (13%)	3,407,511 (11%)	2,753,724 (8.6%)	1,620,872 (4.8%)	
Non-Hispanic White	16,517,618 (61%)	19,183,174 (65%)	20,074,182 (67%)	22,563,107 (70%)	25,436,336 (75%)	
Other	4,222,105 (16%)	4,679,547 (16%)	4,692,437 (16%)	4,785,218 (15%)	5,077,924 (15%)	
education level（%）						<0.001
college graduate or above	8,858,079 (33%)	10,554,847 (36%)	10,014,426 (33%)	9,793,352 (30%)	8,580,788 (25%)	

high school graduate	5,355,101 (20%)	5,240,777 (18%)	6,311,761 (21%)	6,662,530 (21%)	8,705,785 (26%)	
Less_than_high_school	3,517,069 (13%)	3,498,634 (12%)	4,611,526 (15%)	5,503,445 (17%)	6,847,614 (20%)	
some college	9,220,280 (34%)	10,097,493 (34%)	9,066,408 (30%)	10,162,663 (32%)	9,916,691 (29%)	
marriage（%）						<0.001
Marital	12,772,262 (47%)	15,465,115 (53%)	16,940,517 (57%)	19,750,292 (61%)	22,146,542 (65%)	
not married	14,217,854 (53%)	13,931,132 (47%)	13,040,623 (43%)	12,380,152 (39%)	11,897,349 (35%)	
household income（%）						0.091
<20,000	4,570,751 (17%)	4,317,452 (15%)	4,517,036 (16%)	4,521,342 (15%)	4,564,143 (14%)	
20,000–44,900	8,304,960 (32%)	7,243,022 (25%)	8,036,434 (28%)	8,740,016 (28%)	10,476,840 (31%)	
45,000–74,900	4,341,760 (16%)	5,935,649 (21%)	5,930,065 (20%)	6,658,088 (21%)	6,813,519 (20%)	
75,000+	9,101,689 (35%)	11,052,150 (39%)	10,530,735 (36%)	11,136,031 (36%)	11,405,756 (34%)	
BMI（%）						0.5
<18.5	363,696 (1.4%)	388,290 (1.3%)	310,059 (1.0%)	470,671 (1.5%)	525,743 (1.5%)	
>=30	10,910,735 (41%)	11,196,335 (38%)	11,266,457 (38%)	12,448,341 (39%)	12,555,935 (37%)	
18.5 to <25	7,042,874 (26%)	8,327,320 (29%)	8,123,389 (27%)	7,739,361 (24%)	8,991,311 (26%)	
25 to <30	8,272,206 (31%)	9,260,641 (32%)	10,072,986 (34%)	11,315,354 (35%)	11,874,917 (35%)	
smoke（%）						<0.001

current	6,308,268 (23%)	5,278,097 (18%)	4,959,356 (17%)	5,912,814 (18%)	6,564,972 (19%)	
former	4,791,045 (18%)	6,785,173 (23%)	7,922,331 (26%)	8,853,509 (28%)	10,205,723 (30%)	
<100 cigarettes in life or never	15890803(59%)	17332977(59%)	17122432(58%)	17364121(54%)	17280183(51%)	
drink（%）						<0.001
1/day above	642,269 (2.4%)	1,150,175 (3.9%)	841,568 (2.8%)	1,874,297 (5.8%)	3,022,680 (8.9%)	
1/week to <1/day	7,411,936 (27%)	8,977,138 (31%)	9,523,518 (32%)	9,462,485 (29%)	10,410,337 (31%)	
<1/week or never	18935911(70.6%)	19268934(65.1%)	19639033(65.2%)	20793662(65.2%)	20617860(60.1%)	
CKM	8,285,175 (31%)	7,990,455 (27%)	8,600,183 (29%)	8,946,436 (28%)	8,873,435 (26%)	0.3
CKD	4,567,172 (17%)	4,533,591 (15%)	4,537,769 (15%)	4,846,673 (15%)	4,413,985 (13%)	0.3
CVD	3,019,140 (11%)	2,801,268 (9.5%)	3,082,674 (10%)	2,825,569 (8.8%)	3,110,010 (9.1%)	0.5
DM	4,063,762 (15%)	4,498,929 (15%)	4,255,570 (14%)	4,672,221 (15%)	4,293,404 (13%)	0.4
follow time (year)	6.67 (5.67, 7.92)	6.58 (5.75, 7.83)	6.75 (5.75, 7.92)	7.00 (5.92, 7.92)	6.92 (5.83, 8.00)	0.06


A
CKM
P−overall <.0001
P−non−linear = 0.48
OR (95% CI)
Magnitude
B
CKM
age.group
20−39
40−59
60+
C
CKM
sex
female
male
D
CVD
P−overall <.0001
P−non−linear = 0.43
E
CVD
F
CVD
factor(sex)
G
CKD
P−overall <.0001
P−non−linear = 0.43
H
CKD
I
CKD
J
DM
P−overall <.0001
P−non−linear = 0.14
K
DM
L
DM

Figure 1


A
Group
OR (95% CI)
P.trend
CKM
Model1
Q5 (0.438~0.643] 1(ref) <0.001
Q4 (0.378~0.438] 1.24(1−1.54)
Q3 (0.322~0.378] 1.34(1.05−1.69)
Q2 (0.251~0.322] 1.34(1.05−1.72)
Q1 (0.0063~0.251] 1.8(1.41−2.31)
Model2
Q5 (0.438~0.643] 1(ref) <0.001
Q4 (0.378~0.438] 1.28(1.05−1.57)
Q3 (0.322~0.378] 1.35(1.06−1.71)
Q2 (0.251~0.322] 1.38(1.08−1.76)
Q1 (0.0063~0.251] 1.73(1.35−2.21)
Model3
Q5 (0.438~0.643] 1(ref) 0.0014
Q4 0.378,0.4382 1.22(0.95−1.57)
Q3 (0.322~0.378] 1.29(0.97−1.7)
Q2 (0.251~0.322] 1.28(0.96−1.7)
Q1 (0.0063~0.251] 1.61(1.19−2.16)
0.5 1 2.5
Lower risk Higher risk
B
Group
OR (95% CI)
P.trend
CKD
Model1
Q5 (0.438~0.643] 1(ref) <0.001
Q4 (0.378~0.438] 1.33(0.98−1.8)
Q3 (0.322~0.378] 1.32(0.94−1.86)
Q2 (0.251~0.322] 1.5(1.15−1.94)
Q1 (0.0063~0.251] 1.82(1.37−2.4)
Model2
Q5 (0.438~0.643] 1(ref) <0.001
Q4 0.378,0.4381 1.33(0.98−1.8)
Q3 (0.322~0.378] 1.27(0.9−1.79)
Q2 (0.251~0.322] 1.42(1.08−1.86)
Q1 (0.0063~0.251] 1.63(1.21−2.2)
Model3
Q5 (0.438~0.643] 1(ref) <0.001
Q4 0.378,0.4382 1.29(0.91−1.84)
Q3 (0.322~0.378] 1.23(0.83−1.83)
Q2 (0.251~0.322] 1.35(1−1.81)
Q1 (0.0063~0.251] 1.62(1.14−2.3)
0.5 1 2.5
Lower risk Higher risk
C
Group
OR (95% CI)
P.trend
CVD
Model1
Q5 (0.438~0.643] 1(ref) <0.001
Q4 (0.378~0.438] 1.07(0.73−1.59)
Q3 (0.322~0.378] 1.32(0.94−1.87)
Q2 (0.251~0.322] 1.33(0.96−1.83)
Q1 (0.0063~0.251] 1.81(1.37−2.39)
Model2
Q5 (0.438~0.643] 1(ref) <0.001
Q4 0.378,0.4381 1.13(0.75−1.7)
Q3 (0.322~0.378] 1.42(0.98−2.06)
Q2 (0.251~0.322] 1.4(1.02−1.92)
Q1 (0.0063~0.251] 1.84(1.38−2.45)
Model3
Q5 (0.438~0.643] 1(ref) <0.001
Q4 0.378,0.4382 1.07(0.65−1.75)
Q3 (0.322~0.378] 1.39(0.88−2.18)
Q2 (0.251~0.322] 1.26(0.83−1.92)
Q1 (0.0063~0.251] 1.66(1.16−2.37)
0.5 1 2.5
Lower risk Higher risk
D
Group
OR (95% CI)
P.trend
DM
Model1
Q5 (0.438~0.643] 1(ref) <0.001
Q4 (0.378~0.438] 1.3(1.03−1.63)
Q3 (0.322~0.378] 1.3(1.01−1.69)
Q2 (0.251~0.322] 1.54(1.2−1.97)
Q1 (0.0063~0.251] 1.62(1.29−2.02)
Model2
Q5 (0.438~0.643] 1(ref) <0.001
Q4 0.378,0.4381 1.37(1.08−1.73)
Q3 (0.322~0.378] 1.32(0.97−1.78)
Q2 (0.251~0.322] 1.65(1.28−2.11)
Q1 (0.0063~0.251] 1.6(1.28−2)
Model3
Q5 (0.438~0.643] 1(ref) <0.001
Q4 0.378,0.4382 1.27(0.95−1.69)
Q3 (0.322~0.378] 1.21(0.84−1.74)
Q2 (0.251~0.322] 1.42(1.06−1.91)
Q1 (0.0063~0.251] 1.41(1.06−1.87)
0.5 1 2.5
Lower risk Higher risk

Figure 2


E
CKM conditions combination for cancer mortality
heatmap of CKM conditions combination
dm_ckd_cvd 23.2% 21.2% 12.5% 31.4% 43.6%
ckd_cvd 21.6% 31.5% 23.5% 6.0% 18.1%
dm_ckd 12.2% 11.5% 21.0% 5.5% 3.0%
dm_cvd 10.2% 3.8% 3.4% 5.1% 14.9%
ckd 14.6% 9.4% 6.9% 8.3% 3.8%
cvd 9.7% 5.1% 8.7% 11.7% 9.9%
dm 3.4% 2.6% 2.6% 7.2% 2.6%
none 1.8% 1.3% 1.6% 1.6% 2.1%
(0.0063,0.251] (0.251,0.322] (0.322,0.378] (0.378,0.438] (0.438,0.643]
Magnitude5Qcat
Percentage
60
40
20
0
F
the number of ckm conditions for cancer mortality
heatmap of the number of ckm conditions
3 0.0% 5.3% 2.1% 1.3% 6.2%
2 5.1% 3.1% 4.2% 3.2% 4.8%
1 4.4% 4.3% 2.7% 5.7% 3.4%
0 1.1% 0.9% 1.1% 1.2% 1.8%
(0.0063,0.251] (0.251,0.322] (0.322,0.378] (0.378,0.438] (0.438,0.643]
Magnitude5Qcat
Percentage
6
4
2
0
G
CKM conditions combination for premature mortality
heatmap of CKM conditions combination
dm_ckd_cvd 20.9% 10.7% 8.9% 17.9% 14.0%
ckd_cvd 2.6% 12.3% 7.3% 2.0% 9.7%
dm_ckd 22.8% 4.6% 14.7% 11.0% 10.9%
dm_cvd 23.8% 3.7% 4.2% 2.4% 7.3%
ckd 12.7% 6.8% 2.7% 5.1% 0.5%
cvd 4.5% 3.5% 1.9% 2.5% 8.7%
dm 3.5% 10.3% 2.2% 5.3% 3.8%
2.3% 2.1% 1.8% 2.0% 2.6%
Percentage
20
15
10
5
H
the number of ckm conditions fo for premature mortality
heatmap of the number of ckm conditions
3 20.9% 10.7% 8.9% 17.9% 14.0%
2 17.0% 7.0% 9.7% 6.6% 9.5%
1 7.4% 7.8% 2.3% 4.7% 3.6%
0 2.3% 2.1% 1.8% 2.0% 2.6%
Percentage
20
15
10
5

Figure 3


E
CKM conditions combination for cancer mortality
heatmap of CKM conditions combination
dm_ckd_cvd 23.2% 21.2% 12.5% 31.4% 43.6%
ckd_cvd 21.6% 31.5% 23.5% 6.0% 18.1%
dm_ckd 12.2% 11.5% 21.0% 5.5% 3.0%
dm_cvd 10.2% 3.8% 3.4% 5.1% 14.9%
ckd 14.6% 9.4% 6.9% 8.3% 3.8%
cvd 9.7% 5.1% 8.7% 11.7% 9.9%
dm 3.4% 2.6% 2.6% 7.2% 2.6%
none 1.8% 1.3% 1.6% 1.6% 2.1%
(0.0063,0.251] (0.251,0.322] (0.322,0.378] (0.378,0.438] (0.438,0.643]
Magnitude5Qcat
Percentage
60
40
20
0
F
the number of ckm conditions for cancer mortality
heatmap of the number of ckm conditions
3 0.0% 5.3% 2.1% 1.3% 6.2%
2 5.1% 3.1% 4.2% 3.2% 4.8%
1 4.4% 4.3% 2.7% 5.7% 3.4%
0 1.1% 0.9% 1.1% 1.2% 1.8%
(0.0063,0.251] (0.251,0.322] (0.322,0.378] (0.378,0.438] (0.438,0.643]
Magnitude5Qcat
Percentage
6
4
2
0
G
CKM conditions combination for premature mortality
heatmap of CKM conditions combination
dm_ckd_cvd 20.9% 10.7% 8.9% 17.9% 14.0%
ckd_cvd 2.6% 12.3% 7.3% 2.0% 9.7%
dm_ckd 22.8% 4.6% 14.7% 11.0% 10.9%
dm_cvd 23.8% 3.7% 4.2% 2.4% 7.3%
ckd 12.7% 6.8% 2.7% 5.1% 0.5%
cvd 4.5% 3.5% 1.9% 2.5% 8.7%
dm 3.5% 10.3% 2.2% 5.3% 3.8%
2.3% 2.1% 1.8% 2.0% 2.6%
Percentage
20
15
10
5
H
the number of ckm conditions fo for premature mortality
heatmap of the number of ckm conditions
3 20.9% 10.7% 8.9% 17.9% 14.0%
2 17.0% 7.0% 9.7% 6.6% 9.5%
1 7.4% 7.8% 2.3% 4.7% 3.6%
0 2.3% 2.1% 1.8% 2.0% 2.6%
Percentage
20
15
10
5

Figure 4


A
All-cause mortality
P−overall <.0001
P−non−linear = 0.16
HR (95% CI)
B
All-cause mortality
HR (95% CI)
age.group
20−39
40−59
60+
C
All-cause mortality
HR (95% CI)
sex
female
male
D
All-cause mortality
HR (95% CI)
nockm
0
1
2
3
E
Cardiovascular mortality
P−overall <.0001
P−non−linear = 0.39
HR (95% CI)
F
Cardiovascular mortality
HR (95% CI)
age.group
20−39
40−59
60+
G
Cardiovascular mortality
HR (95% CI)
sex
female
male
H
Cardiovascular mortality
HR (95% CI)
nockm
0
1
2
3
I
Cancer mortality
P−overall <.0001
P−non−linear 0.11
HR (95% CI)
J
Cancer mortality
HR (95% CI)
age.group
K
Cancer mortality
HR (95% CI)
sex
female
male
L
Cancer mortality
HR (95% CI)
nockm
0
1
2
3
M
Premature mortality
P−overall <.0001
P−non−linear = 0.69
HR (95% CI)
Magnitude
N
Premature mortality
HR (95% CI)
Magnitude
age.group
20−39
40−59
60+
O
Premature mortality
HR (95% CI)
sex
female
male
Magnitude
P
Premature mortality
HR (95% CI)
nockm
0
1
2
3
Magnitude

Figure 5.


A
Group
HR.95.CI.
P.trend
All-cause mortality
Model1
Q5 (0.438~0.643] Ref <0.01
Q4 (0.378~0.438] 1.02(0.7−1.47)
Q3 (0.322~0.378] 0.98(0.74−1.3)
Q2 (0.251~0.322] 1.09(0.77−1.53)
Q1 (0.0063~0.251] 1.44(1.05−1.99)
Model2
Q5 (0.438~0.643] Ref 0.001
Q4 (0.378~0.438] 1.15(0.78−1.71)
Q3 (0.322~0.378] 1.1(0.79−1.52)
Q2 (0.251~0.322] 1.24(0.85−1.81)
Q1 (0.0063~0.251] 1.75(1.24−2.48)
Model3
Q5 (0.438~0.643] Ref <0.001
Q4 (0.378~0.438] 1.16(0.81−1.67)
Q3 (0.322~0.378] 1.12(0.85−1.47)
Q2 (0.251~0.322] 1.3(0.88−1.92)
Q1 (0.0063~0.251] 1.84(1.37−2.47)
0 1 3
Lower risk Higher risk
B
Group
SHR.95.CI.
P.trend
Cardiovascular mortality
Model1
Q5 (0.438~0.643] Ref 0.001
Q4 (0.378~0.438] 1.23(0.77−1.95)
Q3 (0.322~0.378] 1.35(0.86−2.13)
Q2 (0.251~0.322] 1.42(0.9−2.24)
Q1 (0.0063~0.251] 2.14(1.39−3.28)
Model2
Q5 (0.438~0.643] Ref <0.001
Q4 (0.378~0.438] 1.3(0.8−2.12)
Q3 (0.322~0.378] 1.5(0.92−2.44)
Q2 (0.251~0.322] 1.57(0.97−2.55)
Q1 (0.0063~0.251] 2.27(1.44−3.57)
Model3
Q5 (0.438~0.643] Ref <0.001
Q4 (0.378~0.438] 1.3(0.79−2.15)
Q3 (0.322~0.378] 1.47(0.89−2.44)
Q2 (0.251~0.322] 1.57(0.96−2.57)
Q1 (0.0063~0.251] 2.1(1.31−3.36)
0 1 4
Lower risk Higher risk
C
Group
SHR.95.CI.
P.trend
Cancer mortality
Model1
Q5 (0.438~0.643] Ref ns
Q4 (0.378~0.438] 1.02(0.65−1.6)
Q3 (0.322~0.378] 0.86(0.54−1.36)
Q2 (0.251~0.322] 0.7(0.43−1.14)
Q1 (0.0063~0.251] 0.78(0.48−1.25)
Model2
Q5 (0.438~0.643] Ref
Q4 (0.378~0.438] 1.07(0.68−1.67) ns
Q3 (0.322~0.378] 0.87(0.54−1.41)
Q2 (0.251~0.322] 0.8(0.49−1.31)
Q1 (0.0063~0.251] 0.99(0.61−1.6)
Model3
Q5 (0.438~0.643] Ref ns
Q4 (0.378~0.438] 1.08(0.69−1.69)
Q3 (0.322~0.378] 0.9(0.56−1.45)
Q2 (0.251~0.322] 0.83(0.51−1.36)
Q1 (0.0063~0.251] 1.02(0.62−1.67)
0 1 2
Lower risk Higher risk
D
Group
HR.95.CI.
P.trend
Premature mortality
Model1
Q5 (0.438~0.643] Ref <0.05
Q4 (0.378~0.438] 1.16(0.57−2.37)
Q3 (0.322~0.378] 0.87(0.43−1.76)
Q2 (0.251~0.322] 1.23(0.62−2.43)
Q1 (0.0063~0.251] 1.76(0.92−3.39)
Model2
Q5 (0.438~0.643] Ref ns
Q4 (0.378~0.438] 1.34(0.66−2.72)
Q3 (0.322~0.378] 0.95(0.44−2.04)
Q2 (0.251~0.322] 1.39(0.68−2.86)
Q1 (0.0063~0.251] 1.6(0.81−3.17)
Model3
Q5 (0.438~0.643] Ref <0.05
Q4 (0.378~0.438] 1.43(0.71−2.89)
Q3 (0.322~0.378] 1.05(0.52−2.12)
Q2 (0.251~0.322] 1.68(0.82−3.44)
Q1 (0.0063~0.251] 1.8(0.94−3.43)
0 1 4
Lower risk Higher risk

Figure 6


A
CKM
P−overall <.0001
P−non−linear = 0.19
OR (95% CI)
B
CKM
age.group
20−39
40−59
60+
C
CKM
sex
female
male
D
CKD
P−overall <.0001
P−non−linear = 0.5
E
CKD
F
CKD
factor(sex)
G
CVD
P−non−linear = 0.23
H
CVD
I
CVD
J
DM
P−non−linear = 0.52
K
DM
L
DM
Acrophase

sup-figure 1


A
Group
OR (95% CI)
P.trend
CKM
Model1
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.88(0.77−1)
Q3 (1.88,4.29] 0.98(0.85−1.13)
Q4 (4.29,7.41] 1.09(0.88−1.34)
Q5 (7.41,42.1] 1.19(0.97−1.47)
Model2
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.95(0.82−1.1)
Q3 (1.88,4.29] 1.02(0.87−1.18)
Q4 (4.29,7.41] 1.12(0.9−1.4)
Q5 (7.41,42.1] 1.15(0.91−1.47)
Model3
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.93(0.78−1.11)
Q3 (1.88,4.29] 0.97(0.82−1.15)
Q4 (4.29,7.41] 1.09(0.84−1.4)
Q5 (7.41,42.1] 1.1(0.83−1.46)
0.7 1 1.5
Lower risk Higher risk
B
Group
OR (95% CI)
P.trend
CVD
Model1
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.72(0.58−0.88)
Q3 (1.88,4.29] 0.89(0.68−1.16)
Q4 (4.29,7.41] 0.93(0.72−1.19)
Q5 (7.41,42.1] 0.98(0.72−1.35)
Model2
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.73(0.58−0.92)
Q3 (1.88,4.29] 0.91(0.69−1.19)
Q4 (4.29,7.41] 0.98(0.74−1.3)
Q5 (7.41,42.1] 0.99(0.71−1.39)
Model3
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.74(0.56−0.97)
Q3 (1.88,4.29] 0.88(0.63−1.23)
Q4 (4.29,7.41] 0.97(0.69−1.35)
Q5 (7.41,42.1] 0.95(0.63−1.44)
C
Group
OR (95% CI)
P.trend
CKD
Model1
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.82(0.69−0.99)
Q3 (1.88,4.29] 0.83(0.68−1.01)
Q4 (4.29,7.41] 0.89(0.7−1.12)
Q5 (7.41,42.1] 1(0.79−1.27)
Model2
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.88(0.71−1.1)
Q3 (1.88,4.29] 0.87(0.68−1.1)
Q4 (4.29,7.41] 0.88(0.68−1.14)
Q5 (7.41,42.1] 0.96(0.75−1.23)
Model3
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 0.86(0.67−1.1)
Q3 (1.88,4.29] 0.82(0.64−1.04)
Q4 (4.29,7.41] 0.85(0.63−1.16)
Q5 (7.41,42.1] 0.92(0.68−1.24)
0.5 1 1.5
Lower risk Higher risk
D
Group
OR (95% CI)
P.trend
DM
Model1
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 1.06(0.84−1.35)
Q3 (1.88,4.29] 1.26(0.95−1.66)
Q4 (4.29,7.41] 1.37(1.07−1.75)
Q5 (7.41,42.1] 1.46(1.11−1.92)
Model2
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 1.14(0.89−1.47)
Q3 (1.88,4.29] 1.29(0.97−1.73)
Q4 (4.29,7.41] 1.4(1.08−1.81)
Q5 (7.41,42.1] 1.37(1.03−1.83)
Model3
Q1 (−43,−1.22] 1(ref) <0.001
Q2 (−1.22,1.88] 1.09(0.81−1.47)
Q3 (1.88,4.29] 1.22(0.9−1.65)
Q4 (4.29,7.41] 1.35(0.99−1.83)
Q5 (7.41,42.1] 1.29(0.94−1.77)
0.5 1 2
Lower risk Higher risk

sup-figure 2


A
B
C
D
MORTSTAT
P−overall <.0001
P−non−linear = 0.9
HR (95% CI)
age.group
20−39
40−59
60+
sex
female
male
nockm
0
1
2
3
E
F
G
H
Cardiovascular mortality
P−overall <.0001
P−non−linear = 0.3
I
J
K
L
Cancer mortality
P−overall <.0001
P−non−linear 0.09
M
N
O
P
Premature mortality
P−overall <.0001
P−non−linear = 0.43
Acrophase

sup-figure 3


A
Group
HR.95.CI.
P.trend
All-cause mortality
Model1
Q1 (−43,−1.22] Ref <0.05
Q2 (−1.22,1.88] 1.03(0.79−1.34)
Q3 (1.88,4.29] 0.98(0.72−1.35)
Q4 (4.29,7.41] 0.83(0.61−1.12)
Q5 (7.41,42.1] 0.56(0.4−0.78)
Model2
Q1 (−43,−1.22] Ref ns
Q2 (−1.22,1.88] 1.05(0.82−1.34)
Q3 (1.88,4.29] 1.13(0.81−1.58)
Q4 (4.29,7.41] 1.09(0.82−1.46)
Q5 (7.41,42.1] 0.84(0.62−1.13)
Model3
Q1 (−43,−1.22] Ref ns
Q2 (−1.22,1.88] 1.02(0.8−1.31)
Q3 (1.88,4.29] 1.1(0.82−1.48)
Q4 (4.29,7.41] 1.15(0.88−1.5)
Q5 (7.41,42.1] 0.83(0.63−1.1)
0 1 2
Lower risk Higher risk
B
Group
SHR.95.CI.
P.trend
Cardiovascular mortality
Model1
Q1 (−43,−1.22] Ref <0.001
Q2 (−1.22,1.88] 0.7(0.49−0.99)
Q3 (1.88,4.29] 0.65(0.46−0.93)
Q4 (4.29,7.41] 0.55(0.37−0.82)
Q5 (7.41,42.1] 0.43(0.27−0.68)
Model2
Q1 (−43,−1.22] Ref <0.01
Q2 (−1.22,1.88] 0.69(0.48−1)
Q3 (1.88,4.29] 0.69(0.47−1)
Q4 (4.29,7.41] 0.69(0.45−1.04)
Q5 (7.41,42.1] 0.62(0.39−0.99)
Model3
Q1 (−43,−1.22] Ref <0.05
Q2 (−1.22,1.88] 0.69(0.47−1.02)
Q3 (1.88,4.29] 0.67(0.45−0.98)
Q4 (4.29,7.41] 0.7(0.46−1.08)
Q5 (7.41,42.1] 0.64(0.4−1.04)
0 1 2
Lower risk Higher risk
C
Group
SHR.95.CI.
P.trend
Cancer mortality
Model1
Q5 (0.438~0.643] Ref ns
Q4 (0.378~0.438] 1.02(0.65−1.6)
Q3 (0.322~0.378] 0.86(0.54−1.36)
Q2 (0.251~0.322] 0.7(0.43−1.14)
Q1 (0.0063~0.251] 0.78(0.48−1.25)
Model2
Q5 (0.438~0.643] Ref
Q4 (0.378~0.438] 1.07(0.68−1.67) ns
Q3 (0.322~0.378] 0.87(0.54−1.41)
Q2 (0.251~0.322] 0.8(0.49−1.31)
Q1 (0.0063~0.251] 0.99(0.61−1.6)
Model3
Q5 (0.438~0.643] Ref ns
Q4 (0.378~0.438] 1.08(0.69−1.69)
Q3 (0.322~0.378] 0.9(0.56−1.45)
Q2 (0.251~0.322] 0.83(0.51−1.36)
Q1 (0.0063~0.251] 1.02(0.62−1.67)
0 1 2
Lower risk Higher risk
D
Group
HR.95.CI.
P.trend
Premature mortality
Model1
Q1 (−43,−1.22] Ref ns
Q2 (−1.22,1.88] 0.98(0.58−1.66)
Q3 (1.88,4.29] 0.89(0.42−1.9)
Q4 (4.29,7.41] 1.12(0.6−2.08)
Q5 (7.41,42.1] 0.71(0.36−1.38)
Model2
Q1 (−43,−1.22] Ref ns
Q2 (−1.22,1.88] 1.26(0.75−2.09)
Q3 (1.88,4.29] 1.08(0.53−2.19)
Q4 (4.29,7.41] 1.36(0.75−2.47)
Q5 (7.41,42.1] 0.82(0.45−1.49)
Model3
Q1 (−43,−1.22] Ref ns
Q2 (−1.22,1.88] 1.19(0.7−2.03)
Q3 (1.88,4.29] 1.02(0.53−1.97)
Q4 (4.29,7.41] 1.33(0.77−2.32)
Q5 (7.41,42.1] 0.82(0.45−1.49)
0 1 3
Lower risk Higher risk

sup-figure 4